XORTX Therapeutics Announces 1-For-9 Share Consolidation
Portfolio Pulse from Benzinga Newsdesk
XORTX Therapeutics Inc. has announced a 1-for-9 share consolidation, reducing the number of issued and outstanding shares from 17,989,687 to approximately 1,998,854. The consolidation has been approved by the TSX Venture Exchange and will be effective from November 9, 2023. The shares will continue to trade on the TSXV and the Nasdaq Capital Market under the symbol 'XRTX'.
November 08, 2023 | 10:54 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
XORTX Therapeutics' 1-for-9 share consolidation will significantly reduce the number of outstanding shares, potentially impacting the stock's liquidity and volatility.
Share consolidations can impact a stock's liquidity and volatility. With fewer shares available for trading, the stock may become less liquid and more volatile. However, the impact on the stock price is uncertain as it depends on market reaction to the consolidation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100